Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority-owned subsidiary, Gyre Pharmaceuticals, in the People's Republic of China, and maintains… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Gyre Therapeutics, Inc. does
In the company’s own words
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its majority-owned subsidiary, Gyre Pharmaceuticals, in the People's Republic of China, and maintains U.S. operations headquartered in San Diego, California. More information is available at www.gyretherapeutics.com.
The company has established a commercial foundation in fibrotic diseases through successful development and commercialization of ETUARY (pirfenidone), which generated $106.1 million in annual sales in 2025 and positioned Gyre as a leading participant in pulmonary fibrosis treatment in China. The commercial portfolio also includes Etorel (nintedanib), launched in June 2025 with $4.6 million in 2025 sales, and Contiva (avatrombopag), approved for thrombocytopenia associated with chronic liver disease and chronic idiopathic thrombocytopenia, which generated $5.5 million in 2025 sales.
Gyre's pipeline includes several clinical and preclinical-stage candidates. Hydronidone, the lead development candidate, is being advanced for chronic hepatitis B-associated liver fibrosis in China and metabolic dysfunction-associated steatohepatitis-associated liver fibrosis in the United States. The company reported that Hydronidone met its primary endpoint in a Phase 3 trial for CHB-associated liver fibrosis, with plans to submit a conditional approval application in the first half of 2026. Additional pipeline candidates include F573 for acute liver failure and acute-on-chronic liver failure, F230 for pulmonary arterial hypertension, and F528 for chronic obstructive pulmonary disease, all in development in China. The company is also pursuing label expansion of ETUARY into pneumoconiosis and radiation-induced lung injury.
In March 2026, Gyre entered into a merger agreement with Cullgen Inc., subject to customary closing conditions including stockholder approval and Hart-Scott-Rodino Act clearance. The company's strategy leverages its established commercial portfolio to support advancement of late-stage candidates, expand approved products into additional indications, and build a diversified pipeline addressing significant unmet medical needs in fibrosis and related inflammatory diseases.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1124105
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Gyre Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Gyre Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Gyre Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Gyre Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Gyre Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”